Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis > KOL Insight

KOL Insight


loader
  • Sort by Default
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 30 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Hemophilia KOL Interview – US, Southeast

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed drugs, and late-phase pipeline therapies for hemophilia, including alternative coagulation promoters and gene therapies. Unmet needs are also discussed. The main marketed products covered include Hemlibra, Advate, and BeneFIX, and key pipeline assets highlighted are valoctocogene roxaparvovec (valrox), fitusiran, and concizumab.

    March 20, 2020
    Find out more

  • HER2+ Breast Cancer KOL Interview – UK

    $599.00

    A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include Enhertu, tucatinib, margetuximab, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.

    March 3, 2020
    Find out more

  • HER2+ Breast Cancer KOL Interview – US, West Coast

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include tucatinib, margetuximab, Onzeald, SYD985, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.

    March 3, 2020
    Find out more

  • Multiple Sclerosis (MS) KOL Interview – UK, London

    $599.00

    In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

    March 2, 2020
    Find out more

  • Multiple Sclerosis (MS) KOL Interview – UK, Southwest

    $599.00

    In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

    March 2, 2020
    Find out more

  • Multiple Sclerosis (MS) KOL Interview – US, Midwest

    $599.00

    In this interview, a US-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

    March 2, 2020
    Find out more

  • 2019 ASH Pulse Survey

    $599.00

    This 8-question Pulse survey of 55 hematologic oncologists practicing throughout the United States and Europe asks respondents their thoughts on several topics presented at the 2019 American Society of Hematology (ASH) Annual Meeting. Survey questions and additional resources are listed further below.

    January 10, 2020
    Find out more

  • Type 1 Diabetes KOL Interview – UK

    $599.00

    This interview with a UK Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes.

    January 8, 2020
    Find out more

  • Type 1 Diabetes KOL Interview – US, Midwest

    $599.00

    This interview with a US Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market.

    January 8, 2020
    Find out more

  • Human Papillomavirus (HPV) KOL Interview – Italy

    $599.00

    A European-based key opinion leader (KOL) provides insights into prescribing trends, marketed vaccines, and vaccination coverage rates, as well as commentary on vaccination strategies in different markets. The marketed vaccines discussed include Cervarix, Gardasil, and Gardasil 9.

    January 3, 2020
    Find out more

  • Human Papillomavirus (HPV) KOL Interview – US, Midwest

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing trends, marketed vaccines, and vaccination coverage rates, as well as commentary on vaccination strategies in different markets. The marketed vaccines discussed include Cervarix, Gardasil, and Gardasil 9.

    January 3, 2020
    Find out more

  • Triple-Negative Breast Cancer KOL Interview – UK

    $599.00

    A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

    October 31, 2019
    Find out more

  • Triple-Negative Breast Cancer KOL Interview – US

    $599.00

    A US-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

    October 3, 2019
    Find out more

  • Rheumatoid Arthritis Payer Interview – Pennsylvania, US

    $599.00

    A US payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

    August 22, 2019
    Find out more

  • Rheumatoid Arthritis Payer Interview – UK

    $599.00

    A UK payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

    August 22, 2019
    Find out more

  • Rheumatoid Arthritis KOL Interview – California, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Rheumatoid Arthritis KOL Interview – UK

    $599.00

    A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Rheumatoid Arthritis KOL Interview – New Jersey, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Rheumatoid Arthritis KOL Interview – New Jersey, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Bladder Cancer KOL Interview – US

    $599.00

    A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.

    May 31, 2019
    Find out more

  • Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

    $599.00

    This reimbursement interview with a US key opinion leader (KOL) provides insight into pricing strategies, pricing barriers, and potential reimbursement criteria for non-alcoholic steatohepatitis therapies.

    May 20, 2019
    Find out more

  • Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

    $599.00

    This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.

    May 20, 2019
    Find out more

  • Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

    $599.00

    This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment rates for the different fibrosis stages of NASH. Key pipeline assets highlighted include Ocaliva, elafibranor, cenicriviroc, and firsocostat.

    May 20, 2019
    Find out more

  • Pediatric Epilepsy KOL Interview – US, West

    $599.00

    A US expert in pediatric epilepsy provides insight into the approach to treating different forms of epilepsy. The key opinion leader (KOL) dives into the late-phase pipeline for epilepsy, as well as sharing insight into Epidiolex.

    February 18, 2019
    Find out more

  • Epilepsy KOL Interview – US, West

    $599.00

    A US key opinion leader (KOL) discusses the epilepsy treatment landscape, including new market entrant Epidiolex, and provides their perspective on late-phase pipeline anti-epileptic drugs such as Fintepla.

    February 18, 2019
    Find out more

  • Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – UK

    $599.00

    This interview covers hepatocellular carcinoma (HCC) treatment trends in the UK. We discuss current options for first- and second-line treatment, as well as therapies that are currently in Phase III clinical trials.

    February 6, 2019
    Find out more

  • Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #2

    $599.00

    This interview provides a thorough description of hepatocellular carcinoma (HCC) treatment in the US. All targeted therapies available for HCC treatment are discussed, as well as a discussion of Phase III pipeline drugs and the potential impact these therapies would have if they gain approval.

    February 6, 2019
    Find out more

  • Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #1

    $599.00

    This interview covers hepatocellular carcinoma treatment trends in the US. We discuss current treatment options including the recently approved Keytruda and Lenvima. Also disused are Phase III pipeline therapies Imfinzi and Tecentriq for the first-line setting, along with the potential of PD-1/PD-L1 therapies in the adjuvant setting.

    February 6, 2019
    Find out more

  • Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, West Coast

    $599.00

    A US KOL provides insight into current and future therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.

    February 4, 2019
    Find out more

  • Datamonitor Healthcare Chronic Heart Failure KOL Interview – UK

    $599.00

    A UK KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.

    February 4, 2019
    Find out more
Page 3 of 7
Page 3 of 7‹12345›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top